Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
90,438,636
-
Total 13F shares
-
64,443,699
-
Share change
-
+5,002,739
-
Total reported value
-
$2,536,549,693
-
Put/Call ratio
-
126%
-
Price per share
-
$39.36
-
Number of holders
-
398
-
Value change
-
+$179,624,639
-
Number of buys
-
154
-
Number of sells
-
185
Institutional Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q4 2024
As of 31 Dec 2024 CRISPR Therapeutics AG - Common Stock (CRSP) had 398 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 64,443,699 shares of stock of the company.
Largest 10 holders included ARK Investment Management LLC, Capital International Investors, T. Rowe Price Investment Management, Inc., BlackRock, Inc., Nikko Asset Management Americas, Inc., Sumitomo Mitsui Trust Group, Inc., STATE STREET CORP, FMR LLC, UBS Group AG, and VANGUARD GROUP INC.
This table shows 398 institutional shareholders of the security as of 31 Dec 2024.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.